Dr. James Bruce Leverenz

powered by
COS Expertise®
University of Washington
Neurology and Psychiatry and Behavioral Sciences
Associate ProfessorAppointed: 2003
VA Puget Sound Health Care System
Staff NeurologistAppointed: 1999
University of Washington
School of Medicine
Pediatrics
Center on Human Development and Disability
Research AffiliateAppointed: 1992

Mailing Address

VA-PSHCS
1660 S. Columbian Way
S-116, 6 East
Seattle, Washington 98108
United States

Contact Information

Phone: (206) 277-1047
Fax: (206) 768-5456
leverenz@u.washington.edu

Qualifications

M.D., University of Washington, 1985.

Expertise and Research Interests

Neuropathology of dementia and neurodegenerative disease, including Alzheimer's disease, dementia with Lewy bodies, hippocampal sclerosis, and Parkinson's disease.

Neurobiology of stress, including effects of long-term administration of stress hormones on brain systems.

Keywords

COS Keywords:

Alzheimer's Disease, Dementia, Down Syndrome, Mental Disorders, Neurobiology, Neurodegenerative Diseases, Neurology, Neuropathology, Parkinson's Disease, Pediatrics, Psychiatry, Psychosis, Stress.

Additional Terms:

Alzheimer's Disease, Dementia, Down Syndrome, Lewy Body Dementia, Mental Illness, Neurodegenerative Disease, Parkinson's Disease, Psychosis, Stress.

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)

Memberships

American Academy of Neurology
American Neurological Association
Movement Disorder Society
Society for Neuroscience

Honors and Awards

2002, Research Award in Geriatric Neurology, American Academy of Neurology

Previous Positions

1998-2003, Assistant Professor, University of Washington, School of Medicine, Neurology
1996-1998, Acting Assistant Professor, University of Washington, School of Medicine, Neurology (Primary) and Psychiatry
1992-1996, Acting Instructor, University of Washington, School of Medicine, Medicine (Neurology) and Psychiatry

Funding Received

  • Department of Veterans Affairs: Parkinson's Related Neurodegenerative Dementia in a Community Sample, Oct 1, 2001 to Oct 30, 2004.
  • NIH/NIA: A Clinico-pathologic Study of Frontotemporal Dementia, Alzheimer's Disease Coordinating Center- Collabotative Project, Nov 1, 2000 to Nov 31, 2001.
  • NIH/NIA: Alzheimer's Disease Research Center, Jun 1, 2000 to Jun 30, 2005.
  • National Alzheimer's Coordinating Center: Clinical, Pathologic, and Genetic Characteristics of Dementia with Lewy Bodies: A Multicenter Collaborative Study, Jul 1, 2003 to Jul 30, 2004.
  • NIH/NIA: Psychopathology of Alzheimer's: APOE and the HPA Axis, Jul 1, 2001 to Jul 30, 2006.
  • Veterans Administration Hospital: Mental Illness Research, Education and Clinical Center (MIRECC), Jan 1998 to Dec 1999.
  • NIH: Alzheimer's Disease Research Center (co-investigator), Jan 1995 to Nov 1999.
  • National Institutes of Health (NIH): Characterization of DLB: a Collaborative Study, Dec 1, 2003 to Dec 30, 2008.
  • Department of Veterans Affairs: Psychopathology of Alzheimer's: Psychoneuroendocrinology, Apr 1, 2001 to Apr 31, 2006.
  • National Institutes of Health (NIH): Biomarkers for Parkinson's Disease (PD) and PD Dementia, $250,000/yr, 2004 to 2009.

Publications

  • Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (Oct 2005) Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression., Brain Research. Molecular Brain Research, 139 (2), 367-71 Abstract
  • Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D (Aug 2005) Rate of progression differs in frontotemporal dementia and Alzheimer disease., Neurology, 65 (3), 397-403 Abstract
  • Tsuang DW, Wilson RK, Lopez OL, Luedecking-Zimmer EK, Leverenz JB, DeKosky ST, Kamboh MI, Hamilton RL (Feb 2005) Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease., Neurology, 64 (3), 509-13 Abstract
  • Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S (Feb 2005) Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque., Journal of Neuropathology and Experimental Neurology, 64 (2), 139-46 Abstract
  • Tsuang D, Simpson KL, Li G, Barnhart RL, Edland SD, Bowen J, McCormick W, Teri L, Nochlin D, Larson EB, Thompson ML, Leverenz JB (Apr-Jun 2005) Evaluation of selection bias in an incident-based dementia autopsy case series., Alzheimer Disease and Associated Disorders, 19 (2), 67-73 Abstract
  • McMillan PJ, Wilkinson CW, Greenup L, Raskind MA, Peskind ER, Leverenz JB (Nov 2004) Chronic cortisol exposure promotes the development of a GABAergic phenotype in the primate hippocampus., Journal of Neurochemistry, 91 (4), 843-51 Abstract
  • Riekse RG, Leverenz JB, McCormick W, Bowen JD, Teri L, Nochlin D, Simpson K, Eugenio C, Larson EB, Tsuang D (Sep 2004) Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study., Journal of the American Geriatrics Society, 52 (9), 1442-8 Abstract
  • Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR (Sep 2004) Beta-synuclein gene alterations in dementia with Lewy bodies., Neurology, 63 (5), 805-11 Abstract
  • Doherty MJ, Bird TD, Leverenz JB, Alpha-synuclein in motor neuron disease: an immunohistologic study, Acta Neuropathol, 107, 169-75, 2004
  • Szot P, Wilkinson CW, White SS, Leverenz JB, Greenup JL, Colasurdo EA, Peskind ER, Raskind MA (2004) Chronic cortisol suppresses pituitary and hypothalamic peptide message expression in pigtailed macaques., Neuroscience, 126 (1), 241-6 Abstract
  • McMillan PJ, Peskind E, Raskind MA, Leverenz JB (Nov-Dec 2004) Increased galanin receptor occupancy in Alzheimer's disease., Neurobiology of Aging, 25 (10), 1309-14 Abstract
  • Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD, Neurodegeneration and defective neurotransmission in a Caenorhabditis, Proceedings of the National Academy of Sciences of the United States of America., 100(17), 9980-5, August 2003
  • Bonner LT, Tsuang DW, Cherrier MM, Eugenio CJ, Du Jennifer Q, Steinbart EJ, Limprasert P, La Spada AR, Seltzer B, Bird TD, Leverenz JB, Familial dementia with Lewy bodies with an atypical clinical presentation, Journal of Geriatric Psychiatry and Neurology, 16(1), 59-64, March 2003 Abstract
  • Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S, Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's, American Journal of Pathology, 162(1), 313-9, January 2003
  • Tsuang DW, Dalan AM, Eugenio CJ, Poorkaj P, Limprasert P, La Spada AR, Steinbart EJ, Bird TD, Leverenz JB, Familial dementia with lewy bodies: a clinical and neuropathological study, Archives of Neurology, 59(10), 1622-30, October 2002
  • Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, Flitman S, Winn R, Marciano F, Saul T, Huhn S, Mayo M, McGuire D, Assessment of low-flow CSF drainage as a treatment for AD: results of a, Neurology, 59(8), 1139-45, October 2002
  • Leverenz JB, Agustin CM, Tsuang D, Peskind ER, Edland SD, Nochlin D, DiGiacomo L, Bowen JD, McCormick WC, Teri L, Raskind MA, Kukull WA, Larson EB, Clinical and neuropathological characteristics of hippocampal sclerosis: a, Archives of Neurology, 59(7), 1099-106, July 2002
  • Leverenz JB, McKeith IG, Dementia with Lewy bodies, The Medical Clinics of North America, 86(3), 519-35, May 2002 Abstract
  • Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC, Diet-induced hypercholesterolemia enhances brain A beta accumulation in, Neuroreport, 13(4), 455-9, March 2002
  • Husseman JW, Hallows JL, Bregman DB, Leverenz JB, Nochlin D, Jin LW, Vincent I, Hyperphosphorylation of RNA polymerase II and reduced neuronal RNA levels, Journal of Neuropathology and Experimental Neurology, 60(12), 1219-32, December 2001
  • Leverenz JB, Miller MA, Dobie DJ, Peskind ER, Raskind MA, Increased alpha 2-adrenergic receptor binding in locus coeruleus, Neurobiology of Aging, 22(4), 555-61, 2001
  • Clark AF, Steely HT, Dickerson JE Jr, English-Wright S, Stropki K, McCartney MD, Jacobson N, Shepard AR, Clark JI, Matsushima H, Peskind ER, Leverenz JB, Wilkinson CW, Swiderski RE, Fingert JH, Sheffield VC, Stone EM, Glucocorticoid induction of the glaucoma gene MYOC in human and monkey, Investigative Ophthalmology & Visual Science, 42(8), 1769-80, July 2001
  • Szot P, Leverenz JB, Peskind ER, Kiyasu E, Rohde K, Miller MA, Raskind MA, Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the, Brain Research. Molecular Brain Research, 84(1-2), 135-40, December 2000
  • McMillan PJ, Leverenz JB, Dorsa DM, Specific downregulation of presenilin 2 gene expression is prominent, Brain Research. Molecular Brain Research, 78(1-2), 138-45, May 2000
  • Tsuang D, Larson EB, Bowen J, McCormick W, Teri L, Nochlin D, Leverenz JB, Peskind ER, Lim A, Raskind MA, Thompson ML, Mirra SS, Gearing M, Schellenberg GD, Kukull W, The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer, Archives of Neurology, 56(12), 1489-95, December 1999
  • Miller MA, Kolb PE, Leverenz JB, Peskind ER, Raskind MA, Preservation of noradrenergic neurons in the locus ceruleus that coexpress, Journal of Neurochemistry, 73(5), 2028-36, November 1999
  • Lieberman AP, Trojanowski JQ, Leonard DG, Chen KL, Barnett JL, Leverenz JB, Bird TD, Robitaille Y, Malandrini A, Fischbeck KH, Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease, Annals of Neurology, 46(2), 271-3, August 1999 Abstract
  • Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB, Clinico-neuropathological correlation of Alzheimer's disease in a, Journal of the American Geriatrics Society, 47(5), 564-9, May 1999
  • Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Grabber JE, Raskind MA, Peskind ER, Effect of chronic high-dose exogenous cortisol on hippocampal neuronal, The Journal of Neuroscience : the Official Journal of the Society for Neuroscience., 19(6), 2356-61, March 1999
  • Leverenz JB, Yu CE, Schellenberg GD, Aging-associated neuropathology in Werner syndrome, Acta Neuropathologica, 96(4), 421-4, October 1998 Abstract
  • Leverenz JB, Raskind MA, Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis., Experimental Neurology, 150(2), 296-304, April 1998 Abstract
  • Leverenz JB, Yu CE, Schellenberg GD, Aging-associated neuropathology in Werner syndrome, Acta Neuropathol., 96, 421-424, 1998
  • Peskind ER, Leverenz J, Farlow MR, Ito RK, Provow SA, Siegel RS, Cleveland M, Morgan CH, Pandian MR, Corbin S, Nochlin D, Schellenberg GD, Raskind MA, Wagner SL, Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls., Alzheimer Disease and Associated Disorders, 11(4), 201-6, December 1997 Abstract
  • Edland SD, Wijsman EM, Schoder-Ehri GL, Leverenz JB, Little evidence of reduced survival to adulthood of apoE epsilon4 homozygotes in Down's syndrome., Neuroreport, 8(16), 3463-5, November 1997 Abstract
  • Matsushima H, Peskind ER, Clark JM, Leverenz JB, Wilkinson CW, Clark JI, Protein changes during aging and the effects of long-term cortisol treatment in macaque monkey lens., Optometry and Vision Science, 74(4), 190-7, April 1997 Abstract
  • Tsuang D, Raskind MA, Leverenz J, Peskind ER, Schellenberg G, Bird TD, The effect of apolipoprotein E genotype on expression of an autosomal dominant schizophreniform disorder with progressive dementia and neurofibrillary tangles., Biological Psychiatry, 41(2), 191-5, January 1997 Abstract
  • McMillan PJ, Leverenz JB, Poorkaj P, Schellenberg GD, Dorsa DM, Neuronal expression of STM2 mRNA in human brain is reduced in Alzheimer's disease., Journal of Histochemistry and Cytochemistry, 44(11), 1215-22, November 1996 Abstract
  • Borson S, Leverenz JB, Basic mechanisms in neurodegenerative disease: Implications for behavioral pathogenesis and treatment., Seminars in Clinical Neuropsychiatry, 1, 248-60, 1996
  • Frumkin LR, Patterson BK, Leverenz JB, Agy MB, Wolinsky SM, Morton WR, Corey L, Infection of Macaca nemestrina brain with human immunodeficiency virus type 1., Journal of General Virology, 76 ( Pt 10), 2467-76, October 1995 Abstract
  • Leverenz JB, Dementia. Epidemiology, diagnosis and medical management of Alzheimer's disease., Proc. Straub Found., 59, 12-5, 1995
  • Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS, Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease., Neurobiology of Aging, 14(6), 589-96, 1993 Abstract
  • Rye DB, Leverenz J, Greenberg SG, Davies P, Saper CB, The distribution of Alz-50 immunoreactivity in the normal human brain., Neuroscience, 56(1), 109-27, September 1993 Abstract
  • Leverenz J, Sumi SM, Parkinson's disease in patients with Alzheimer's disease., Archives of Neurology, 43(7), 662-4, July 1986 Abstract
  • Cohen D, Eisdorfer C, Leverenz J, Alzheimer's disease and maternal age., Journal of the American Geriatrics Society, 30(10), 656-9, October 1982 Abstract
  • Cohen D, Eisdorfer C, Prinz P, Leverenz J, Davis M, Immunoglobulins, cognitive status and duration of illness in Alzheimer's disease., Neurobiology of Aging, 1 (2), 165-8, 1980

Profile Details

Last Updated: 3/31/2008

COS Expertise ID #424157
Reference this profile directly: http://myprofile.cos.com/leverenzj